Targeted cancer drug shows promise but study halted early
Disease control
Terminated
This study tested a drug called tovorafenib in people aged 12 and older whose cancers had returned or worsened and had certain gene changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Day One Biopharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:47 UTC